FAculty directory

Back to alphabetical index

Xiao-Feng Yang, MD, PhD, FAHA

Professor, Pharmacology

Professor, Cardiovascular Research Center

Professor, Sol Sherry Thrombosis Research Center

Temple University School of Medicine

3500 N. Broad Street

Medical Education and Research Building, Room 1059

Philadelphia, PA 19140

Telephone:  215-707-5985

Departmental Fax:  215-707-5737

Email: xfyang@temple.edu

Department of Pharmacology

Cardiovascular Research Center

Sol Sherry Thrombosis Research Center

MD, Clinical Medicine, JiangXi Medical University, China 1979      

 

MS, Immunology, Chinese National Academy of Medical Sciences and Peking Union Medical University 1982    

 

PhD, Biochemistry and Molecular Biology, University of Montreal, Canada 1994 

 

Fellowship, Immunology and oncology, Harvard Medical School, 1999

Return to top

Dr. Xiao-Feng Yang’s laboratory focuses on studying the regulatory mechanisms of immune responses: The First issue is the regulation of immune responses by modulating T lymphocyte survival and apoptosis. Our publications have demonstrated that a novel interplay between Bcl-xL apoptosis-regulatory family members, such as Bcl-xL, and a novel cytosolic anti-apoptotic protein TCTP plays an essential role in the regulation of T cell apoptosis. Identification of the interplays in the apoptosis regulatory pathways in T cell subsets could lead to novel therapeutic intervention to autoimmune diseases and tumors. The second issue is the regulation of autoimmune and anti-tumor immune responses by modulating self-antigen repertoire. Our results have demonstrated that alternative splicing and overexpression are among the key molecular events in selection of the self-antigen repertoire. We have proposed for the first time a new model of stimulation-responsive splicing as one of the general mechanisms of autoantigen selection. Elucidation of the mechanisms underlying selection of autoantigens and self-tumor antigens provides important foundation for future development of antigen-specific immunotherapies as well as diagnostic and prognostic tools for tumors and autoimmune diseases.

Return to top

Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

16931800. Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, Yang F, Durante W, Chan L, Schafer AI, Pownall HJ, Yang X, Wang H, Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99:6(598-606)2006 Sep 15

16800912. Ke XY, Wang J, Yang XF, [New principles in tumor antigens and their significance in future immunotherapies for lymphomas and other malignancies--editorial]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14:3(419-26)2006 Jun

16226235. Tan H, Jiang X, Yang F, Li Z, Liao D, Trial J, Magera MJ, Durante W, Yang X, Wang H, Hyperhomocysteinemia inhibits post-injury reendothelialization in mice. Cardiovasc Res 69:1(253-62)2006 Jan

16210565. Jiang X, Yang F, Tan H, Liao D, Bryan RM Jr, Randhawa JK, Rumbaut RE, Durante W, Schafer AI, Yang X, Wang H, Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 25:12(2515-21)2005 Dec

12506016. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang X, Berger PB, Durante W, Pownall HJ, Schafer AI, Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 101:10(3901-7)2003 May 15